Team

EvoBiotech’s team is led by a passionate group of distinguished scientists, skilled researchers, expert managers and business strategists, with a background in the pharmaceutical industry or in pharmaceutical research.

Meet our team

Chief Executive Officer (CEO)

Marco Dieci

Curriculum

Career:

He served as CEO at Holostem, Executive Director at the facility of Children Hospital Bambino Gesù in Rome, CEO of Xellbiogene, and Operations Director at MolMed.

Education:

Master’s Degree in Chemistry, University of Parma

Expertise:

25 years of management experience in the life science industry, specifically in clinical operations management, pharma business development and market access. Covering different role such as CEO, Executive Director and Chief Operating Officer for the management of Biotech Products & Advance Therapies Medicinal Products in the fields of Clinical and Operation development and Regulatory Affairs, Technology transfer, scale up & industrialization.

Co-founder and Scientific Advisor

Giovanni Camussi

Curriculum

Career:

Emeritus Professor at University of Turin, he has been Full Professor of Nephrology  at University of Turin, Adjoint Professor of Medicine at Brown University, Full Professor of Nephrology and Clinical Immunology at University of Pavia, and Full Professor at the II University of Naples.

Administrative Experiences:

At University of Turin, he has been Director of the PhD program in Medical Pathophysiology, Member of the Council of the School of Medicine, Director of the Stem Cell Laboratory at Molecular Biotechnology Centre, Renal Immunopathology Laboratory at Department of Medical Sciences, Vascular and Renal, Physiopathology at Centro di Medicina Sperimentale (CeRMS), President of Scientific Committee of Translational Center for Regenerative Medicine, President of the Course of Medical Biotechnology, Director of Department of Internal Medicine and of the PhD school in complex systems in medicine and Life sciences.

Expertise:

The scientific activity was focused on: 1. the biochemical characterization, cellular origin and biological activities of platelet-activating factor, 2. experimental models of kidney and lung injury, 3. marrow and tissue derived stem cell separation and characterization, 4. renal immunopathology, 5. inflammatory and tumour angiogenesis, 6. purification and characterization of stem cell derived extracellular vesicles and characterization of their mRNA and miRNA content. In particular, he investigated the role of extracellular vesicles in the paracrine action of progenitors/stem cells and their possible therapeutic applications.

He has been the principal investigator of several research programs funded by Ministero dell’Istruzione, Università e Ricerca (MIUR), Consiglio Nazionale delle Ricerche (CNR), Associazione Italiana per la Ricerca sul Cancro (AIRC), Consorzio Nazionale per la Ricerca sulle Cellule Staminali (CONSTEM), European Foundation for the Study of Diabetes, CEE, Kistem Project, European 6th Framework Programme on Research, Technological Development and Demonstration, and Marie Curie Actions; Nanotechnology.

He served as referee for the following research agencies: Wellcome Trust (UK); Cancer Research UK; Canadian Institutes of Health Research; Natural Sciences and Engineering Research Council of Canada; German Federal Ministry of Education and Research, Ministero Istruzione Università e Ricerca, Istituto Superiore di Sanità, Israel Science Foundation, Swiss National Science Foundation, National Institutes of Health (NIH), USA.

He served in the Editorial Board of several journals, including PLosOne, American Journal of Cancer Research, Journal of Nephrology, International Journal of Molecular Medicine, and as referee for several journals, including Blood, Nature Medicine, Journal Experimental Medicine, The Journal of American Society of Nephrology, Journal of Immunology.

Co-founder and Scientific Advisor

Maria Chiara Deregibus

Curriculum

Career:

Expert Senior Researcher. She worked for several years at University of Turin (Incubatore 2i3T, Centro di Medicina Sperimentale – CeRMS) and previously at Buffalo General Hospital (Renal Immunopathology Laboratory). She collaborated with several pharmaceutical companies such as Fresenius Medical Care and SiS-Ter S.p.A. Maria Chiara holds several patents and scientific publications.

Education:

Specialization in Hygiene, University of Turin

Master’s Degree in Medicine and Surgery, University of Turin

Expertise:

Scientific activity was carried on in the field of inflammation and angiogenesis, oncology, cell and stem cell biology. She is an expert on extracellular vesicles derived from stem cells or biologic fluids (serum, plasma, saliva) and their biochemical characterization (protein, mRNA, miRNA content), isolation methods, biologic activities (paracrine signalling of progenitor stem cells), possible therapeutic and diagnostic applications. She was among the first scientists to describe the ability of extracellular vesicles to transport functional nucleic acids to target cells.

Marco Dieci

Chief Executive Officer (CEO)

Curriculum

Career:

He served as CEO at Holostem, Executive Director at the facility of Children Hospital Bambino Gesù in Rome, CEO of Xellbiogene, and Operations Director at MolMed.

Education:

Master’s Degree in Chemistry, University of Parma

Expertise:

25 years of management experience in the life science industry, specifically in clinical operations management, pharma business development and market access. Covering different role such as CEO, Executive Director and Chief Operating Officer for the management of Biotech Products & Advance Therapies Medicinal Products in the fields of Clinical and Operation development and Regulatory Affairs, Technology transfer, scale up & industrialization.

Giovanni Camussi

Co-founder and Scientific Advisor

Curriculum

Career:

Emeritus Professor at University of Turin, he has been Full Professor of Nephrology  at University of Turin, Adjoint Professor of Medicine at Brown University, Full Professor of Nephrology and Clinical Immunology at University of Pavia, and Full Professor at the II University of Naples.

Administrative Experiences:

At University of Turin, he has been Director of the PhD program in Medical Pathophysiology, Member of the Council of the School of Medicine, Director of the Stem Cell Laboratory at Molecular Biotechnology Centre, Renal Immunopathology Laboratory at Department of Medical Sciences, Vascular and Renal, Physiopathology at Centro di Medicina Sperimentale (CeRMS), President of Scientific Committee of Translational Center for Regenerative Medicine, President of the Course of Medical Biotechnology, Director of Department of Internal Medicine and of the PhD school in complex systems in medicine and Life sciences.

Expertise:

The scientific activity was focused on: 1. the biochemical characterization, cellular origin and biological activities of platelet-activating factor, 2. experimental models of kidney and lung injury, 3. marrow and tissue derived stem cell separation and characterization, 4. renal immunopathology, 5. inflammatory and tumour angiogenesis, 6. purification and characterization of stem cell derived extracellular vesicles and characterization of their mRNA and miRNA content. In particular, he investigated the role of extracellular vesicles in the paracrine action of progenitors/stem cells and their possible therapeutic applications.

He has been the principal investigator of several research programs funded by Ministero dell’Istruzione, Università e Ricerca (MIUR), Consiglio Nazionale delle Ricerche (CNR), Associazione Italiana per la Ricerca sul Cancro (AIRC), Consorzio Nazionale per la Ricerca sulle Cellule Staminali (CONSTEM), European Foundation for the Study of Diabetes, CEE, Kistem Project, European 6th Framework Programme on Research, Technological Development and Demonstration, and Marie Curie Actions; Nanotechnology.

He served as referee for the following research agencies: Wellcome Trust (UK); Cancer Research UK; Canadian Institutes of Health Research; Natural Sciences and Engineering Research Council of Canada; German Federal Ministry of Education and Research, Ministero Istruzione Università e Ricerca, Istituto Superiore di Sanità, Israel Science Foundation, Swiss National Science Foundation, National Institutes of Health (NIH), USA.

He served in the Editorial Board of several journals, including PLosOne, American Journal of Cancer Research, Journal of Nephrology, International Journal of Molecular Medicine, and as referee for several journals, including Blood, Nature Medicine, Journal Experimental Medicine, The Journal of American Society of Nephrology, Journal of Immunology.

Maria Chiara Deregibus

Co-founder and Scientific Advisor

Curriculum

Career:

Expert Senior Researcher. She worked for several years at University of Turin (Incubatore 2i3T, Centro di Medicina Sperimentale – CeRMS) and previously at Buffalo General Hospital (Renal Immunopathology Laboratory). She collaborated with several pharmaceutical companies such as Fresenius Medical Care and SiS-Ter S.p.A. Maria Chiara holds several patents and scientific publications.

Education:

Specialization in Hygiene, University of Turin

Master’s Degree in Medicine and Surgery, University of Turin

Expertise:

Scientific activity was carried on in the field of inflammation and angiogenesis, oncology, cell and stem cell biology. She is an expert on extracellular vesicles derived from stem cells or biologic fluids (serum, plasma, saliva) and their biochemical characterization (protein, mRNA, miRNA content), isolation methods, biologic activities (paracrine signalling of progenitor stem cells), possible therapeutic and diagnostic applications. She was among the first scientists to describe the ability of extracellular vesicles to transport functional nucleic acids to target cells.

Co-founder and R&D Project Manager

Chiara Gai

Curriculum

Career:

Senior Researcher. She worked as a Post-doctoral fellow at University of Turin in Renal Immunopathology Laboratory and Physiopathology of Atherosclerosis Laboratory. She co-founded EvoBiotech in 2019 and served as chairperson until 2021. Chiara holds several patents and scientific publications.

Education:

PhD in Medical Physiopathology at the Doctoral School of Health and Life Science, University of Turin.

Master’s Degree in Medical Biotechnology, University of Turin.

Expertise:

Scientific activity was carried on in the field of inflammation and angiogenesis, diabetes, regenerative medicine, cell and stem cell biology. She is an expert on molecular characterization (protein, mRNA, miRNA content) and study of the biologic activities (angiogenesis, migration, anti-oxidant activity) of extracellular vesicles derived from stem cells, biologic fluids (serum, plasma, saliva), and plants. She is dedicated to the development of a large-scale production method of plant derived extracellular vesicles.

Co-founder and R&D Project Manager

Margherita Pomatto

Curriculum

Career:

Senior Researcher. She worked as a Post-doctoral fellow at University of Turin in Stem Cell Laboratory, Physiopathology of Atherosclerosis Laboratory, and Renal Immunopathology Laboratory. She co-founded EvoBiotech in 2019 and served as CEO until 2021. Margherita holds several patents and scientific publications.

Education:

PhD in Medical Physiopathology at the Doctoral School of Health and Life Science, University of Turin.

Master’s Degree in Medical Biotechnology, University of Turin.

Expertise:

Scientific activity was carried on in the field of cell and stem cell biology, oncology, regenerative medicine, inflammation and angiogenesis. She is an expert on extracellular vesicles as therapeutic agents, delivery system, and diagnostic tool. Her experience regards the molecular characterization (protein and nuclei acid content) and the study of multiple biologic activities (e.g. angiogenesis, proliferation, migration, anti-oxidant activity) of extracellular vesicles derived from stem cells, biologic fluids (e.g. serum, plasma, saliva), and plants. She is a specialist in several techniques for loading extracellular vesicles with nucleic acids and other drugs.

R&D Associate

Federica Negro

Curriculum

Career:

She worked as a Researcher in EvoBiotech since 2021 and previously in Unicyte Italia and in collaboration with the University of Turin. 

Education:

Master’s Degree in Medical Biotechnology, University of Turin.

Expertise:

Scientific activity was carried on in the field of stem cell biology, fibrosis, angiogenesis, and regenerative medicine. She is an expert on isolation, characterization, and functional study of extracellular vesicles derived from stem cells and plants. She masters cell culture and molecular biology techniques, flow cytometry, biological and biochemical assays in vitro. She is trained in several techniques for loading extracellular vesicles with nucleic acids and other drugs.

Chiara Gai

Co-founder and R&D Project Manager

Curriculum

Career:

Senior Researcher. She worked as a Post-doctoral fellow at University of Turin in Renal Immunopathology Laboratory and Physiopathology of Atherosclerosis Laboratory. She co-founded EvoBiotech in 2019 and served as chairperson until 2021. Chiara holds several patents and scientific publications.

Education:

PhD in Medical Physiopathology at the Doctoral School of Health and Life Science, University of Turin.

Master’s Degree in Medical Biotechnology, University of Turin.

Expertise:

Scientific activity was carried on in the field of inflammation and angiogenesis, diabetes, regenerative medicine, cell and stem cell biology. She is an expert on molecular characterization (protein, mRNA, miRNA content) and study of the biologic activities (angiogenesis, migration, anti-oxidant activity) of extracellular vesicles derived from stem cells, biologic fluids (serum, plasma, saliva), and plants. She is dedicated to the development of a large-scale production method of plant derived extracellular vesicles.

Margherita Pomatto

Co-founder and R&D Project Manager

Curriculum

Career:

Senior Researcher. She worked as a Post-doctoral fellow at University of Turin in Stem Cell Laboratory, Physiopathology of Atherosclerosis Laboratory, and Renal Immunopathology Laboratory. She co-founded EvoBiotech in 2019 and served as CEO until 2021. Margherita holds several patents and scientific publications.

Education:

PhD in Medical Physiopathology at the Doctoral School of Health and Life Science, University of Turin.

Master’s Degree in Medical Biotechnology, University of Turin.

Expertise:

Scientific activity was carried on in the field of cell and stem cell biology, oncology, regenerative medicine, inflammation and angiogenesis. She is an expert on extracellular vesicles as therapeutic agents, delivery system, and diagnostic tool. Her experience regards the molecular characterization (protein and nuclei acid content) and the study of multiple biologic activities (e.g. angiogenesis, proliferation, migration, anti-oxidant activity) of extracellular vesicles derived from stem cells, biologic fluids (e.g. serum, plasma, saliva), and plants. She is a specialist in several techniques for loading extracellular vesicles with nucleic acids and other drugs.

Federica Negro

R&D Associate

Curriculum

Career:

She worked as a Researcher in EvoBiotech since 2021 and previously in Unicyte Italia and in collaboration with the University of Turin. 

Education:

Master’s Degree in Medical Biotechnology, University of Turin.

Expertise:

Scientific activity was carried on in the field of stem cell biology, fibrosis, angiogenesis, and regenerative medicine. She is an expert on isolation, characterization, and functional study of extracellular vesicles derived from stem cells and plants. She masters cell culture and molecular biology techniques, flow cytometry, biological and biochemical assays in vitro. She is trained in several techniques for loading extracellular vesicles with nucleic acids and other drugs.

R&D Associate

Lucia Massari

Curriculum

Career:

She worked as a Researcher in EvoBiotech since 2021 and in Microbiology and in the Food Technology Laboratory, University of Turin.

Education:

Master’s Degree in Plant Biotechnology, University of Turin.

Expertise:

Scientific activity was carried on in the field of microbiology and bioengineering.  She is an expert in isolation, characterization, and functional study of extracellular vesicles derived from plants. She masters cell culture and molecular biology techniques, bacterial culture, flow cytometry, biological and biochemical assays in vitro. She is trained in large-scale production method of plant derived extracellular vesicles.

Lucia Massari

R&D Associate

Curriculum

Career:

She worked as a Researcher in EvoBiotech since 2021 and in Microbiology and in the Food Technology Laboratory, University of Turin.

Education:

Master’s Degree in Plant Biotechnology, University of Turin.

Expertise:

Scientific activity was carried on in the field of microbiology and bioengineering.  She is an expert in isolation, characterization, and functional study of extracellular vesicles derived from plants. She masters cell culture and molecular biology techniques, bacterial culture, flow cytometry, biological and biochemical assays in vitro. She is trained in large-scale production method of plant derived extracellular vesicles.

Partners

SOCIETÀ PER LA GESTIONE DELL’INCUBATORE DI IMPRESE E PER IL TRASFERIMENTO TECNOLOGICO DELL’UNIVERSITÀ DEGLI STUDI DI TORINO SCARL – 2I3T

2i3T is the company for the management of the business incubator and for the technology transfer of the Turin’s University, that takes care of enhancing the results of academic research in an economic key, by promoting and supporting the creation of new companies with a high knowledge content.

2i3T it’s an hub were Innovative ideas, future entrepreneur, industry needs, investors and finance meet to boost new intensive knowledge startups.

Investors

SCOUTING, INVESTING IN AND NURTURING HEALTHCARE INNOVATION

Nocturnal Labs is an operational holding company that supports seed stage companies in developing products, technologies, and global businesses that that make a significant advance in healthcare.

In addition to investing in companies developing pharmaceutical, biotechnology and medical products, Nocturnal Labs invests in businesses that provide services in drug and medical device discovery, development, and other potential important services to the healthcare industry.